Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a prostate cancer poster session. Dr. Ida Sonni presented a study evaluating the diagnostic performance of 18 ...
GlobalData on MSN4d
Radiopharm’s imaging molecule hits mark in observational trialThe company’s RAD 101 imaging molecule identified brain tumours in all 12 treatment-naïve patients in a proof-of-concept ...
F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach ...
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 ...
Radiopharm Theranostic (RADX)s announced the publication of a novel imaging approach demonstrating proof-of-concept for the use of RAD 101 for ...
Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer. PYLCLARI® (INN: Piflufolastat (1 ...
METHODS: One hundred ten patients with gliomas who underwent [18F]FET PET/MR scanning were retrospectively analyzed. The TRFET over MR was identified by the discrepancy-PET that the extent of ...
Scientists have developed two new imaging agents that work better than the only currently approved one for detecting tau tangles in the brain. Tau tangles are abnormal protein clumps linked to ...
Life Molecular Imaging (LMI), an international pharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging, announces that the U.S. Food and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback